Immune-mediated pathology as a consequence of impaired immune reactions Research Program
Immune-mediated pathology as a consequence of impaired immune reactions
Immune-mediated pathology as a consequence of impaired immune reactions
Immune-mediated pathology as a consequence of impaired immune reactions

The goal of the CRC 1160

The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.

The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.

Research Program
More Seminars

News

More News

Publications

van Otterdijk, S. D., H. Klett, M. Boerries, and K. B. Michels. 2023. The impact of pre-pregnancy folic acid intake on placental DNA methylation in a fortified cohort. FASEB J 37: e22698. doi: 10.1096/fj.202200476RR.

Rapp, J., M. Jung, R. F. U. Klar, J. Wolf, J. Arnold, O. Gorka, O. Gross, C. Lange, H. Agostini, G. Schlunck, and F. Bucher. 2022. STAT3 signaling induced by IL-6 family cytokines modulates angiogenesis. J Cell Sci. :jcs.260182. doi: 10.1242/jcs.260182.

Ruckert, T., G. Andrieux, M. Boerries, K. Hanke-Muller, N. M. Woessner, S. Doetsch, C. Schell, K. Aumann, J. Kolter, A. Schmitt-Graeff, M. Schiff, L. M. Braun, E. Haring, S. Kissel, B. A. Siranosian, A. S. Bhatt, P. Nordkild, J. Wehkamp, B. A. H. Jensen, S. Minguet, J. Duyster, R. Zeiser, and N. Kohler. 2022. Human beta-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med 14: eabp9675. doi: 10.1126/scitranslmed.abp9675.

Rush-Kittle, J., L. Gamez-Diaz, and B. Grimbacher. 2022. Inborn errors of immunity associated with defects of self-tolerance checkpoints: The CD28 family. Pediatr Allergy Immunol 33: e13886. doi: 10.1111/pai.13886.

More Publications